SMTI (Sanara MedTech) Cyclically Adjusted Revenue per Share: $7.61 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMTI Sanara MedTech Inc SMTI
72 GF Score
Price $25.00
GF Value $45.80
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Sanara MedTech Cyclically Adjusted Revenue per Share?

Sanara MedTech SMTI -1.26% 72 Cyclically Adjusted Revenue per Share is $7.61 as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.80 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sanara MedTech's adjusted revenue per share for the three months ended in Mar. 2026 was $3.094. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $7.61 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sanara MedTech's average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sanara MedTech was 14.30% per year. The lowest was 5.60% per year. And the median was 9.80% per year.

As of today (2026-07-19), Sanara MedTech's current stock price is $25.00. Sanara MedTech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $7.61. Sanara MedTech's Cyclically Adjusted PS Ratio of today is 3.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sanara MedTech was 12.08. The lowest was 0.71. And the median was 4.47.


Sanara MedTech  (NAS:SMTI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sanara MedTech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=25.00/7.61
=3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sanara MedTech was 12.08. The lowest was 0.71. And the median was 4.47.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sanara MedTech Cyclically Adjusted Revenue per Share Related Terms


Sanara MedTech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sanara MedTech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech Cyclically Adjusted Revenue per Share Chart

Sanara MedTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 4.89 5.56 6.37 7.30

Sanara MedTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.60 6.86 7.09 7.30 7.61

SMTI vs EMBC, KRMD, UTMD: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Sanara MedTech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanara MedTech Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's Cyclically Adjusted PS Ratio falls into.


SMTI
72GF Score
Sanara MedTech Inc SMTI
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanara MedTech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sanara MedTech's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.094/330.2130*330.2130
=3.094

Current CPI (Mar. 2026) = 330.2130.

Sanara MedTech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.159 241.018 1.588
201609 1.300 241.428 1.778
201612 1.591 241.432 2.176
201703 0.774 243.801 1.048
201706 1.298 244.955 1.750
201709 1.393 246.819 1.864
201712 1.491 246.524 1.997
201803 1.235 249.554 1.634
201806 0.956 251.989 1.253
201809 0.662 252.439 0.866
201812 0.020 251.233 0.026
201903 5.907 254.202 7.673
201906 1.275 256.143 1.644
201909 1.230 256.759 1.582
201912 0.939 256.974 1.207
202003 0.568 258.115 0.727
202006 0.478 257.797 0.612
202009 0.686 260.280 0.870
202012 0.761 260.474 0.965
202103 0.735 264.877 0.916
202106 0.837 271.696 1.017
202109 0.775 274.310 0.933
202112 0.934 278.802 1.106
202203 1.027 287.504 1.180
202206 1.185 296.311 1.321
202209 1.609 296.808 1.790
202212 1.887 296.797 2.099
202303 1.899 301.836 2.078
202306 1.915 305.109 2.073
202309 1.923 307.789 2.063
202312 2.110 306.746 2.271
202403 2.202 312.332 2.328
202406 2.380 314.175 2.501
202409 2.545 315.301 2.665
202412 3.083 315.605 3.226
202503 2.734 319.799 2.823
202506 2.999 322.561 3.070
202509 2.945 324.800 2.994
202512 3.181 324.054 3.241
202603 3.094 330.213 3.094

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $7.61 mean?
Sanara MedTech (SMTI) has a Cyclically Adjusted Revenue per Share of $7.61 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sanara MedTech and its competitors.
Is Sanara MedTech's Cyclically Adjusted Revenue per Share too high?
Sanara MedTech's current Cyclically Adjusted Revenue per Share is $7.61. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Cyclically Adjusted Revenue per Share compare to EMBC and KRMD?
Sanara MedTech's Cyclically Adjusted Revenue per Share of $7.61 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sanara MedTech and its competitors. Sanara MedTech's current Cyclically Adjusted Revenue per Share is $7.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.80, compared to a current price of $25.00 — trading 45.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $7.61. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Cyclically Adjusted Revenue per Share is $7.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanara MedTech (SMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued. The current stock price of $25.00 is trading 45.4% below its estimated GF Value™ of $45.80. GuruFocus considers Sanara MedTech to be Possible Value Trap.

Key valuation signals for SMTI:

  • Cyclically Adjusted Revenue per Share: $7.61
  • GF Value™: $45.80 vs. price of $25.00 (45.4% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanara MedTech Business Description

Address 1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score

Get the complete analysis for SMTI

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price
$45.80
GF Value